FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167938710> ?p ?o ?g. }

• W3167938710 endingPage "TPS6089" @default.
• W3167938710 startingPage "TPS6089" @default.
• W3167938710 abstract "TPS6089 Background: PD-1 blockade ± chemotherapy has recently become a primary systemic therapy recommended by NCCN guidelines for patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, most pts still do not respond to treatment, indicating a large unmet need for pts with unresectable disease. CMP-001 is a toll-like receptor 9 (TLR9) agonist comprising a CpG-A oligodeoxynucleotide packaged in a virus-like particle that can induce type I interferon secretion from tumor-associated plasmacytoid dendritic cells, promoting a Th1-like chemokine milieu in the tumor microenvironment and inducing an antitumor CD8+ T-cell response. In a phase (ph) 1b study in pts with metastatic melanoma, intratumoral (IT) injection of CMP-001 + intravenous (IV) pembrolizumab (pembro) reversed PD-1 blockade resistance, induced responses in injected and noninjected lesions, and had an acceptable safety profile (Milhem et al, SITC 2020). This combination is therefore being tested in pts with HNSCC. Methods: CMP-001-007 (NCT04633278) is an open-label, multicenter, ph 2 study designed to investigate the efficacy and safety of CMP-001 + IV pembro in adult pts with histologically or cytologically confirmed R/M HNSCC considered incurable by local therapies. Eligible pts have undergone a pretreatment tumor biopsy, received no prior systemic therapy in the R/M setting, and have primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. In addition, pts must have PD-L1-positive tumors (combined positive score ≥1), known tumor human papillomavirus (HPV) status (for oropharyngeal cancer), and measurable disease per RECIST v1.1 with ≥1 lesion amenable to IT injection. Pts with primary tumors in the nasopharynx are excluded. Enrolled pts will receive CMP-001 10 mg once weekly for 7 doses and every 3 weeks (Q3W) thereafter. The first dose may be administered subcutaneously or via IT injection, with all subsequent doses administered IT. All pts will also receive pembro 200 mg IV Q3W after the CMP-001 injection. Treatment continues until unacceptable toxicity or disease progression. The primary endpoint is investigator-assessed objective response rate (ORR) per RECIST v1.1. Secondary endpoints include safety, duration of response (DOR), progression-free survival (PFS), overall survival, and effects of HPV infection and PD-L1 expression on ORR, DOR, and PFS. Exploratory endpoints include analyses of baseline and changes from baseline in tumor or serum biomarkers related to TLR9, immune checkpoints, and potential predictors of response, as well as serum concentrations of CXCL10 and CMP-001. Refer to clinicaltrials.gov/ct2/show/NCT04633278 for the most current information on enrolling sites. Clinical trial information: NCT04633278." @default.
• W3167938710 created "2021-06-22" @default.
• W3167938710 creator A5005266772 @default.
• W3167938710 creator A5013519961 @default.
• W3167938710 creator A5032809504 @default.
• W3167938710 creator A5034255925 @default.
• W3167938710 creator A5042882441 @default.
• W3167938710 creator A5058393482 @default.
• W3167938710 creator A5058605525 @default.
• W3167938710 creator A5061656341 @default.
• W3167938710 creator A5067324005 @default.
• W3167938710 creator A5074279819 @default.
• W3167938710 creator A5086131239 @default.
• W3167938710 date "2021-05-20" @default.
• W3167938710 modified "2023-10-01" @default.
• W3167938710 title "CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma." @default.
• W3167938710 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps6089" @default.
• W3167938710 hasPublicationYear "2021" @default.
• W3167938710 type Work @default.
• W3167938710 sameAs 3167938710 @default.
• W3167938710 citedByCount "1" @default.
• W3167938710 countsByYear W31679387102022 @default.
• W3167938710 crossrefType "journal-article" @default.
• W3167938710 hasAuthorship W3167938710A5005266772 @default.
• W3167938710 hasAuthorship W3167938710A5013519961 @default.
• W3167938710 hasAuthorship W3167938710A5032809504 @default.
• W3167938710 hasAuthorship W3167938710A5034255925 @default.
• W3167938710 hasAuthorship W3167938710A5042882441 @default.
• W3167938710 hasAuthorship W3167938710A5058393482 @default.
• W3167938710 hasAuthorship W3167938710A5058605525 @default.
• W3167938710 hasAuthorship W3167938710A5061656341 @default.
• W3167938710 hasAuthorship W3167938710A5067324005 @default.
• W3167938710 hasAuthorship W3167938710A5074279819 @default.
• W3167938710 hasAuthorship W3167938710A5086131239 @default.
• W3167938710 hasConcept C121608353 @default.
• W3167938710 hasConcept C126322002 @default.
• W3167938710 hasConcept C143998085 @default.
• W3167938710 hasConcept C2776107976 @default.
• W3167938710 hasConcept C2776530083 @default.
• W3167938710 hasConcept C2776694085 @default.
• W3167938710 hasConcept C2776833033 @default.
• W3167938710 hasConcept C2777701055 @default.
• W3167938710 hasConcept C2778822529 @default.
• W3167938710 hasConcept C2779984678 @default.
• W3167938710 hasConcept C2780057760 @default.
• W3167938710 hasConcept C71924100 @default.
• W3167938710 hasConceptScore W3167938710C121608353 @default.
• W3167938710 hasConceptScore W3167938710C126322002 @default.
• W3167938710 hasConceptScore W3167938710C143998085 @default.
• W3167938710 hasConceptScore W3167938710C2776107976 @default.
• W3167938710 hasConceptScore W3167938710C2776530083 @default.
• W3167938710 hasConceptScore W3167938710C2776694085 @default.
• W3167938710 hasConceptScore W3167938710C2776833033 @default.
• W3167938710 hasConceptScore W3167938710C2777701055 @default.
• W3167938710 hasConceptScore W3167938710C2778822529 @default.
• W3167938710 hasConceptScore W3167938710C2779984678 @default.
• W3167938710 hasConceptScore W3167938710C2780057760 @default.
• W3167938710 hasConceptScore W3167938710C71924100 @default.
• W3167938710 hasIssue "15_suppl" @default.
• W3167938710 hasLocation W31679387101 @default.
• W3167938710 hasOpenAccess W3167938710 @default.
• W3167938710 hasPrimaryLocation W31679387101 @default.
• W3167938710 hasRelatedWork W2738397398 @default.
• W3167938710 hasRelatedWork W2743577629 @default.
• W3167938710 hasRelatedWork W2768318314 @default.
• W3167938710 hasRelatedWork W2898449356 @default.
• W3167938710 hasRelatedWork W2963491961 @default.
• W3167938710 hasRelatedWork W2971369959 @default.
• W3167938710 hasRelatedWork W3000701650 @default.
• W3167938710 hasRelatedWork W3021512745 @default.
• W3167938710 hasRelatedWork W3090002302 @default.
• W3167938710 hasRelatedWork W4323657820 @default.
• W3167938710 hasVolume "39" @default.
• W3167938710 isParatext "false" @default.
• W3167938710 isRetracted "false" @default.
• W3167938710 magId "3167938710" @default.
• W3167938710 workType "article" @default.